Zimbabwe has declined a substantial American health deal worth 367 million US dollars (272 million pounds) spanning five years over Washington's request for sensitive biological samples.
This rejection became public after a internal memorandum dated December was leaked, which showed President Emmerson Mnangagwa deemed the agreement was "skewed".
A government spokesperson later clarified that the United States was seeking health data for scientific study and commercial purposes while was not willing to guarantee the resulting advantages from future vaccines.
"We must now begin the challenging and unfortunate process of scaling back our health aid in Zimbabwe," remarked American envoy to Zimbabwe Pamela Tremont publicly.
Her embassy indicated the United States had furnished more than $1.9bn in health funding to Zimbabwe over the last twenty years.
A medical body in Zimbabwe has called for more dialogue to find a agreement agreeable to all parties so the nation's critical HIV programme can continue.
Broader Context
This rejection follows a similar situation in neighbouring Kenya, where a court blocked a similar deal with the US following legal challenges were raised about the safety of Kenyans' health data.
After returning to office last year, US President Donald Trump has reduced foreign aid and closed the US Agency for International Development (USAID).
The agency had overseen assistance for the American government, but Trump argued its spending was "wasteful" and his administration was pursuing government-to-government deals to enhance transparency and accountability.
Based on reports, Sixteen African countries have so far agreed to these new health pacts, representing over $18.3bn in committed funds.
Details of the Declined Deal
This assistance for Zimbabwe would have funded "combating HIV/Aids, TB, malaria, maternal and child health, and disease outbreak preparedness.
"We believe this collaboration might have yielded significant benefits for Zimbabwean communities, particularly the 1.2 million men, women and children presently on antiretroviral therapy via American-funded initiatives," Tremont added.
However, official spokesman Nick Mangwana maintained the proposed deal was "unfair".
"The proposal required Zimbabwe to share its biological resources and data indefinitely, with no corresponding promise of benefiting from any medical innovations – like new medicines or tests – that might be developed from that provided information," Mangwana explained.
"Effectively, our country would provide the raw materials for scientific discovery with no certainty that the end products would be available to our population should a future disease outbreak arise."
Sovereignty and International Frameworks
He also noted that the US's withdrawal from the World Health Organization (WHO) and its push of one-on-one health agreements were upending frameworks already set up through the global health agency.
The spokesperson cited its Pathogen Access and Benefit Sharing system created to manage future pandemics.
"This framework is intended to ensure that when a nation contributes its samples, the benefits – including medicines and cures – are distributed fairly, not commercialised solely by those with the resources to create them."
These objections over the US deal "must not be interpreted as anti-American sentiment," Mangwana stressed.
"We encourage continued discussions with our US partners on how future collaboration might be designed in a manner that respects the sovereignty and interests of each country."
Health Experts Response
Medical experts expressed it understood the official position, but suggested that talks must proceed since much of the nation's Aids initiatives relied on external financing.
"In cases where specific concerns arise, such as those relating to data governance or agreement terms, these can often be resolved via technical clarification and negotiated safeguards," the group said.
The situation highlights the ongoing tensions between accepting vital international aid and safeguarding a country's data in an increasingly data-driven world.